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Transgenic porcine cancer models bring novel possibilities for research. Their
physical similarities with humans enable the use of surgical procedures and
treatment approaches used for patients, which facilitates clinical translation.
Here, we aimed to develop an inducible oncopig model of intestinal cancer.
Transgenic (TG) minipigs were generated using somatic cell nuclear transfer by
handmade cloning. The pigs encode two TG cassettes: (a) an Flp recombinase-
inducible oncogene cassette containing KRAS-G12D, cMYC, SV40LT – which
inhibits p53 – and pRB and (b) a 4-hydroxytamoxifen (4-OHT)-inducible Flp
recombinase activator cassette controlled by the intestinal epithelium-specific vil-
lin promoter. Thirteen viable transgenic minipigs were born. The ability of 4-
OHT to activate the oncogene cassette was confirmed in vitro in TG colonic
organoids and ex vivo in tissue biopsies obtained by colonoscopy. In order to
provide proof of principle that the oncogene cassette could also successfully be
activated in vivo, three pigs were perorally treated with 400 mg tamoxifen for
2 9 5 days. After two months, one pig developed a duodenal neuroendocrine
carcinoma with a lymph node metastasis. Molecular analysis of the carcinoma
and metastasis confirmed activation of the oncogene cassette. No tumor forma-
tion was observed in untreated TG pigs or in the remaining two treated pigs.
The latter indicates that tamoxifen delivery can probably be improved. In sum-
mary, we have generated a novel inducible oncopig model of intestinal cancer,
which has the ability to form metastatic disease already two months after induc-
tion. The model may be helpful in bridging the gap between basic research and
clinical usage. It opens new venues for longitudinal studies of tumor develop-
ment and evolution, for preclinical assessment of new anticancer regimens, for
pharmacology and toxicology assessments, as well as for studies into biological
mechanisms of tumor formation and metastasis.
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1. Introduction
In cancer research, animal models play an important
role for establishing a link between basic research and
clinical application. Numerous rodent models have
been developed for studying intestinal cancer. They
have provided insights into pathogenic mechanisms,
served as tools for discovery and validation of novel
therapeutic targets and for testing chemoprevention
strategies (Le Magnen et al., 2016). However, no
rodent model fully mimics human intestinal carcino-
genesis (Washington et al., 2013; Young et al., 2013).
The limitations of rodents as models of human cancer
include large differences in lifespan, size, and physiol-
ogy. To augment studies in mice, new animal models
of cancer are needed. The pig is a promising alterna-
tive model organism due to its high degree of similar-
ity to humans, including longevity, size, organ
anatomy, physiology, drug metabolism, genetics, and
immunology (Flisikowska et al., 2013; Forster et al.,
2010; Kuzmuk and Schook, 2011; Manno et al., 2016;
Mote and Rothschild, 2006; Wernersson et al., 2005).
Importantly, the large size of pigs also brings opportu-
nities for longitudinal sampling and therefore monitor-
ing of tumor evolution during treatment, which is
generally not possible in rodents.
Throughout the industrialized countries, intestinal
cancers are among the most common malignancies
(Siegel et al., 2016). The molecular mechanisms under-
lying intestinal oncogenesis is well described (Fearon
and Vogelstein, 1990; Wood et al., 2007), which is
essential for generating relevant transgenic (TG) ani-
mal models. Cancers arising from the intestinal epithe-
lium are believed to start as benign adenomatous
polyps, a process often initiated by the activation of
canonical Wnt signaling, that enables the cells to avoid
the normal differentiation and exfoliation from the
intestinal wall (Krausova and Korinek, 2014). Most
commonly, Wnt is activated through mutational inacti-
vation of the tumor suppressor gene APC leading to
upregulation of downstream Wnt targets, such as
cMYC (Finch et al., 2009). A pig model of human
familial adenomatous polyposis (FAP) syndrome was
recently reported (Flisikowska et al., 2012). In line
with humans, the FAP model developed multiple
benign polyps; however, so far no malignant tumors
have been reported (Flisikowska et al., 2012). Other
recent oncopig models addressed human Li-Fraumeni
syndrome (Sieren et al., 2014). In one model, the onco-
pigs were homozygous for the TP53-R167H mutation
and developed numerous tumors throughout the body
in resemblance with the human disease (Leuchs et al.,
2012). Another model allowed for more controllable
tumor formation – spatial and temporal – by encoding
Cre recombinase-inducible TP53-R167H and KRAS-
G12D (Schook et al., 2015). Upon injection of Cre-
expressing adenovirus, these pigs developed various
mesenchymal tumors at the injection site. Common for
the two models are their lack of tissue specificity and
the formation of tumors of multiple cellular origins.
Here, we present a novel oncopig model with induci-
ble intestinal-specific carcinogenesis leading to rapid
formation of metastatic carcinoma. TG minipigs were
created by porcine somatic cell nuclear transfer (Du
et al., 2005; Schmidt et al., 2010). The model encodes
two TG cassettes: (a) a flippase (Flp) recombinase-
inducible oncogene cassette containing KRAS-G12D,
cMYC, and simian virus-40-large T (SV40LT) antigen
and (b) a 4-hydroxytamoxifen (4-OHT)-inducible Flp
recombinase activator cassette (Flp-ERT2) controlled
by the villin promoter, which is specifically expressed
in the epithelium of the intestinal mucosa (El Marjou
et al., 2004; Kucherlapati et al., 2006; Madison et al.,
2002). The model enables induction of intestinal car-
cinogenesis through the activation of KRAS and
cMYC oncogenic signaling and through SV40LT-
mediated inactivation of the tumor suppressors, p53
(Bargonetti et al., 1992; Lilyestrom et al., 2006) and
pRB (Resnick-Silverman et al., 1991). This oncopig
model represents an exciting disease model for intesti-
nal cancer, as it opens a range of possibilities for lon-
gitudinal studies of intestinal cancer development,
metastatic disease, and therapy response.
2. Materials and methods
All animal experiments were conducted and approved
by the Danish Animal Experiments Inspectorate
(license no. 2012-15-2934-00031 and 2014-15-0201-
00433) and adhered to ARRIVE. The G€ottingen Elle-
gaard minipigs (Ellegaard G€ottingen Minipigs A/S,
Denmark) were housed and cared for in accordance
with the Danish Animal Research Proposal on geneti-
cally modified animals and the EU Directive 2010/63/
EU for animal experiments.
2.1. Cassette construction
The oncogene cassette was constructed in multiple
cloning steps. The following plasmids were used in the
construction: the pLVCT-rtTR-KRAB-2SM2
(Addgene plasmid #11779), and the pBABE-puro-
SV40LT (Addgene plasmid #13970); the YFP-F2A-
KRAS (isoform-B) G12D-T2A-cMYC, CAG-RFP,
and the TRE element were ordered from GenScript
(Piscataway, NJ, USA). The activator cassette was
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constructed from the following plasmids: 12.4-kb mur-
ine villin promoter (Addgene plasmid #19358), blue
fluorescent protein (BFP) mTurquoise2 (Addgene plas-
mid #54842) (Goedhart et al., 2012), PGK-FlpO
(codon optimized), and Cre-ERT2 (gifts from Frank
Schn€utgen, Goethe University, Germany). Both cas-
settes included left and right inverted repeats (LIR and
RIR) and LoxP elements from the floxed-Ei-Ubi-
PSEN1M146I plasmid described in Jakobsen et al.
(2013). The oncogene and activator cassette are avail-
able from Addgene (deposited as Addgene plasmid
#67277 and #67278, respectively).
2.2. Transfection and selection of cell clones
Fibroblasts from female neonate minipig ear notch
biopsies were cultured in DMEM (Lonza, Basel,
Switzerland), supplied with 15% FBS, 1% penicillin/
streptomycin (P/S), and 1% glutamine (Sigma-Aldrich,
St. Louis, MO, USA). Fibroblasts at 50–60% conflu-
ence were cotransfected with 40 ng circular Sleeping
Beauty 100X (Mates et al., 2009), 560 ng oncogene,
and 3400 ng activator cassette (1 : 7) using 6 lL Tur-
boFect lipofectamine (Thermo Fisher Scientific, Wal-
tham, MA, USA). Puromycin (1.6 lgmL1 –
14 days)-resistant colonies were isolated and expanded
with bovine FGF supplied (14 ngL1). RFP+/BFP
colonies validated by PCR to contain both the TG
cassettes were used for cloning.
2.3. Handmade cloning (HMC), embryo culture,
and transfer
HMC was performed as described by Kragh et al.
(2004, 2009) with improvement by Du et al. (2005)
using oriented, bisected, enucleated oocytes with par-
tially digested zonae pellucidae. In brief, serum-starved
cell clones were attached 1 : 1 with a cytoplast and
fused (BTX microslide 0.5 mm fusion chamber, model
450 BTX San Diego, US). Each cytoplast–TG fibrob-
last pair was fused with a second cytoplast creating a
reconstructed embryo. Reconstructed embryos were
incubated and cultivated for 5–6 days before surgically
transferred into Danish landrace surrogate sows (Du
et al., 2007; Schmidt et al., 2010). The farrowing was
hormonally initiated at day 114 by intramuscularly
injected prostaglandin, resulting in 13 viable TG
minipigs.
2.4. Southern blot analysis
Genomic DNA (gDNA) was isolated from chorionic
villi-lysed neonatal ear biopsies, and Southern blotting
of 6 lg gDNA, digested by 1.5 Ulg1 DNA EcoRV
and BstZ17I (Thermo Fisher Scientific), on nitrocellu-
lose membrane was performed as described (Jakobsen
et al., 2011). The RFP and Flp DNA probes (705 and
777 bp) were purified from restriction-cleaved plasmid
DNA and labeled with 32P-dCTP EasyTide (Perkin
Elmer, Waltham, MA, USA) using the Prime-It Ran-
dom Labeling Kit (Agilent Technologies, Santa Clara,
CA, USA). X-ray films were developed at 70 °C for
48–72 h.
2.5. Long-distance inverted PCR (LDI-PCR)
LDI-PCR was performed as previously described
(Al-Mashhadi et al., 2013). In brief, gDNA isolated
from fetal TG fibroblasts was digested with Bsu36I
and PacI (Thermo Fisher). DNA was circularized by
T4 ligase (Thermo Fisher) and used as template in a
two-round nested PCR setup to produce flanking
genomic sequence. The DNA was Sanger-sequenced
and the upstream genomic sequence was mapped to
the pig genome (Groenen et al., 2012) (S. scrofa 10.2).
Primers are listed in Table S1.
2.6. IVIS optical imaging of organ fluorescence
Ex vivo epifluorescence imaging of pig organs was per-
formed with the IVIS spectrum system (Perkin
Elmer). Laser and filter settings for RFP (570/640 nm,
20 nm), YFP (500/540 nm, 20 nm), and BFP (430/
500 nm, 20 nm) were applied. Fixed illumination set-
tings (voltage, f/stop, field of view, and binning) were
used, and fluorescence emission was normalized to
photons per second per square centimeter per steradian
over lamp watt per square centimeter [ps1cm2sr1]/
[lWcm2] designated as mean radiant efficiency. The
adaptive fluorescent background and tissue autofluo-
rescence were subtracted in spectral unmixing and only
photon counts > 600 were analyzed. Image and data
analyses were performed with LIVING IMAGE 4.3 (Perkin
Elmer). The WT organs were coimaged to set autoex-
posure according to the brightness of the tissue and to
automatically reduce false-positive signal.
2.7. Quantitative PCR
RT-qPCR and qPCR were performed using SYBR
Green I Master Mix (Roche, Basel Switzerland)
according to the manufacturer’s instructions. All RT-
qPCR and qPCR measurements were made on a
LightCycler 480 (Roche). The BFP and RFP allelic
copy numbers were estimated from TG ear notch
biopsy DNA and normalized to porcine GLIS3. Total
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RNA from fibroblast and fresh frozen tissue was puri-
fied using Maxwell 16 LEV simplyRNA (Promega,
Madison, WI, USA) according to the manufacturer’s
guidelines. cDNA was synthesized using iScriptTM
Select cDNA Synthesis Kit (Bio-Rad, Hercules, CA,
USA). No-RT controls were included to identify and
exclude samples with contaminating gDNA. Relative
expression levels were determined using the compara-
tive Ct method (Livak and Schmittgen, 2001) and nor-
malized to a geometric mean of the three reference
genes RPL4, HPRT1, and TBP (Nygard et al., 2007;
Vandesompele et al., 2002). Primer sequences are
shown in Table S1.
2.8. Flp recombination validation by PCR and
digital droplet PCR (ddPCR)
For Flp recombination validation by PCR, 20 ng of
gDNA was PCR-amplified with Q5 Hot Start High-
Fidelity polymerase (NEB, MA, USA), 200 lM dNTP,
10 pmol forward (a) and 10 pmol reverse primer (b)
multiplied in 35 cycles PCR (Tan. 62 °C, 15 s and Tex.
72 °C 1 min 10 s).
Droplet digital PCR (ddPCR) quantification of allelic
copy numbers was performed on a QX100TM ddPCR
system according to the manufacturer’s instructions
(Bio-Rad). TaqMan assays for quantifying the porcine
genome (3–4), the oncogene cassette (5–6), and the Flp-
activated oncogene cassette (7–8) were profiled. The
ddPCR data were analyzed using QuantaSoftTM (Bio-
Rad). Primer and probe sequences are listed in Table S1.
2.9. Flow cytometry
Puromycin-resistant colonies were harvested and ana-
lyzed on an LSRFortessa flow cytometer (BD Bio-
science, NJ, USA). Single-cell gating and background
fluorescent subtraction were applied before evaluation
of the fluorescence signal. Laser and filter settings for
RFP (561/630 nm, 22 nm), YFP (488/530 nm, 30 nm),
and BFP (405/442 nm, 46 nm) were applied. To
account for fluorescence spillover, negative controls,
fluorescent minus one, and single reporter positive
controls were analyzed for all reporter combinations.
Results were analyzed using FLOWJO 10.0.7 (Tree Star
Inc., Ashland, OR, USA).
2.10. Western blotting
Protein extraction and western blotting was performed
using standard procedures. In brief, 30 lg protein per
sample was separated by Bolt Bis-Tris 4–12% SDS/
PAGE (Thermo Fisher) and blotted onto
polyvinylidene fluoride (PVDF) by iBlot (Invitrogen,
Carlsbad, CA, USA) and blocked by 4% skim milk in
2% Tris-buffered saline/Tween. Primary antibodies
used in this study were as follows: 2A peptide 1 : 2000
ABS31 (Millipore, Billerica, MA, USA), SV40LT
1 : 400 Pab416 (Abcam, Cambridge, UK), and b-actin
1 : 10 000 AC-15 (Abcam). Secondary horseradish
peroxidase (HRP) antibodies used in this study were
as follows: goat anti-rabbit (AP156P; Millipore) and
rabbit anti-mouse (ab97046; Abcam).
2.11. Endoscopy
Pigs were given a single rectal enema of 45 mL Phos-
phoral (ATC-code: A06AD) 1 h prior to endoscopy,
which was performed with an Olympus GIF-Q180 gas-
troscope. The pigs were anesthetized by (1 mL per
15 kg body mass) intramuscular injection of Zoletil 50
Vet. mixture (125 mg zolazepam, tiletamine, 125 mg
ketamine, 125 mg xylazine, and 25 mg butorphanol).
Postoperatively, the pigs were given analgesics and
water and fed ad libitum.
2.12. 4-OHT treatment of porcine intestinal
organoids and mucosa biopsies
Pig intestinal mucosa samples were collected and stored
in 4 °C transport medium consisting of advanced
DMEM/F12 with 1% P/S (Life Technologies, Carlsbad,
CA, USA) and 2.5 lgmL1 amphotericin (Sigma-
Aldrich). The isolation of crypts for organoid formation
was performed essentially as previously described (Sato
et al., 2011), although with a modified chelation buffer
of PBS supplemented with 30 mM EDTA (Life Tech-
nologies) and 0.5 mM DTT (Sigma-Aldrich). Crypts were
suspended in (1 : 2) PBS and growth factor-reduced
Matrigel (BD Biosciences, San Jose, CA, USA), which
was polymerized for 30 min at 37 °C and covered in
organoid medium containing advanced DMEM/F12,
supplemented with 1% P/S, 10 mM HEPES, 50 ngmL1
mEGF, 1x GlutaMax (all from Life Technologies),
1 mM N-acetylcysteine, 10 lM SB202190 (Sigma-
Aldrich), 100 ngmL1 noggin (PeproTech, Rocky Hill,
NJ, USA), 500 nM A-83-01 (Tocris), 25% Wnt-3A-con-
ditioned medium, and 25% R-spondin1-conditioned
medium (Sato et al., 2011). Mouse L-cells expressing
Wnt-3A were kindly provided by Hans Clevers,
Hubrecht Institute, The Netherlands, whereas Hek293T
cells expressing R-spondin1 were kindly provided by
Calvin Kuo, Stanford University, USA. The organoids
were grown at 37 °C in a 5% CO2 humidified incubator.
For testing oncogene cassette activation, in vitro
organoids and ex vivo intestinal biopsies were cultured
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in organoid medium and DMEM 1% P/S + 10%
FBS, respectively. Activation was performed with
1 lM 4-OHT (Sigma-Aldrich) for a minimum of 24 h
before cell lysis and DNA purification. An overview of
the usage of minipigs is shown in Fig. S3.
2.13. Immunohistochemistry
Tissues sections (4 lm) fixed in 10% formaldehyde
and embedded in paraffin received antigen retrieval at
100 °C in citrate buffer. Sections were blocked in
2.5% BSA in PBS + 0.1% Tween 20 and the following
primary antibodies were used: synaptophysin (MRQ-
40), CD56 (MRQ-42), CDX-2 (EPR2764Y), Ki67 (30-
9) (Ventana Roche, Tucson, AZ, USA) and SV40LT
(Pab416; Abcam). Secondary antibodies were coupled
to HRP, and counterstaining was performed with
hematoxylin. The proportion of positively stained cells
was estimated using Fiji (Schindelin et al., 2012).
3. Results
3.1. Generation of TG intestinal cancer minipigs
TG primary neonate G€ottingen minipig fibroblasts
were generated by Sleeping Beauty transposase-
mediated integration of two cassettes into the pig gen-
ome: an oncogene and an activator cassette (Fig. 1A,
B). The oncogene cassette consists of two parts driven
by a ubiquitous CAG promoter. The first part consists
of RFP and a puromycin selection gene followed by a
polyA stop element, which prevents expression of the
second part of the cassette. The first part is flanked by
FRT sites and can be excised upon expression of Flp
recombinase. Excision of the first part promotes
expression from the second oncogene element. The
polycistronic oncogene element consists of YFP and
three oncogenes separated by 2A linker peptides:
KRAS-G12D, WT cMYC, and SV40LT (Fig. 1A). The
activator cassette is driven by the intestinal-specific vil-
lin promoter and encodes a BFP as well as a Flp
recombinase fused to the triple mutant form of the
human estrogen receptor (Flp-ERT2), which does not
bind its natural ligand (17b-estradiol) at physiological
concentrations, but will bind the estrogen receptor
ligand 4-OHT (Fig. 1B). In the absence of 4-OHT, the
Flp-ERT2 fusion protein will be located in the cyto-
plasm and accordingly the Flp-ERT2 is unable to
mediate DNA recombination. However, in the pres-
ence of 4-OHT, the fusion protein translocates to the
nucleus and the Flp-ERT2 recombinase activity
becomes active (Brocard et al., 1997; Reinert et al.,
2012). The intestinal cancer cell line CaCo2, primary
fibroblast, and embryonic kidney cell line HEK293T
were used to confirm tissue-specific expression of the
villin promoter (Fig. S1A) and to test its activity
(Fig. S1B) compared with CAG and CMV promoters.
Nuclear translocation and activation of the Flp-ERT2
recombinase can be induced by treatment with 4-OHT.
The oncogene cassette furthermore includes two termi-
nal tet-responsive elements (TRE) and a reverse tetra-
cycline repressor-fused Kr€uppel-associated box
KRAB-off element, enabling conditional inhibition of
oncogene expression by doxycycline (DOX) (Groner
et al., 2012; Szulc et al., 2006). Additionally, the onco-
gene cassette contains two Dre recombinase recogni-
tion sites (Rox), enabling termination of oncogene
expression through excision (Fig. 1A). For cloning of
TG minipigs, 18 puromycin-resistant colonies were
harvested. Of these, nine contained both cassettes.
Four showed a single integrated oncogene cassette and
multiple integrated activator cassettes (Fig. S2A). The
latter are beneficial as a positive correlation is expected
between the Flp level and the likelihood of activating
the oncogene cassette. The five remaining clones were
mixed populations of wild-type (WT) and TG cells
and were excluded from further analysis. As expected,
the four selected clones expressed RFP, but not BFP
or YFP (Fig. S2B). All four clones were expanded and
forced into G0 by serum starvation, electrofused with
enucleated oocytes, and cultured for 5–6 days. Two
pools of cloned TG embryos containing either 80 blas-
tocysts or 66 blastocysts + 14 morulas were prepared
and transferred into two recipient landrace surrogate
sows. The sows farrowed 13 TG minipigs, giving a
total cloning efficiency of 8.9% from the initial blasto-
cysts. Figure 1C illustrates the cloning procedure. An
overview of how the 13 TG minipigs were used in this
study is provided in Fig. S3. Southern blotting of the
13 TG minipigs revealed integration of one oncogene
cassette and indicated six activator cassettes (Fig. 1D,
E). Unexpectedly, all TG minipigs showed the same
bands for both cassettes, indicating that they all origi-
nated from the same clone. Using LDI-PCR, the inte-
gration site of the oncogene cassette was mapped to
an intergenic region on chromosome 13 (13;
121620509–121520689) S. scrofa 10.2, between the
genes NLGN1 and NAALADL2 (Fig. 1F). Subsequent
genomic PCR spanning from the cassette and into the
neighboring region on chromosome 13 identified the
same integration site in all 13 minipigs (Fig. S2C), sup-
porting that the 13 TG pigs originated from the same
clone. Importantly, the resulting TG minipigs showed
unaffected embryogenesis and development, indicating
that the integration sites of the oncogene and activator
cassettes in this clone did not implicate essential genes.
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3.2. Tissue specificity of the activator and
oncogene cassettes
To assess the tissue specificity of the cassettes, the
BFP, RFP, and YFP fluorescence in selected organs
from untreated TG pigs (n = 2) was measured by IVIS
analysis. WT animals (n = 2) were used as negative
controls (Figs 2 and S4). The expression of BFP from
the activator cassettes was primarily seen in the
mucosa of the intestine, while RFP from the oncogene
cassette was ubiquitously expressed in both intestinal
(rectum, colon, ileum, jejunum, duodenum, and
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Fig. 1. Genetic design of the porcine intestinal cancer model. (A) The inducible polycistronic oncogene cassette is a Sleeping Beauty
transposon controlled by a CAG promoter. The cassette consists of two parts: The first part encodes a red fluorescent protein (RFP)
reporter and a puromycin N-acetyl transferase. Its transcription is terminated by a strong polyadenylation site, which prevents read-through
into the second part. Flp recombinase recognition target sites (FRT) flank the first part and enable excision. The second part consists of
yellow fluorescent protein (YFP) and three oncogenes KRAS-G12D, cMYC and SV40LT flanked by Dre recombinase recognition target sites
(ROX). Expression from the oncogene cassette can be terminated by Dre recombination or inhibited using the doxycycline-responsive
element rtTR-KRAB docking at the Tet-responsive elements (TRE); (B) the FlpO-inducible activator cassette is also a Sleeping Beauty
transposon. Expression from the cassette is controlled by an intestinal-specific villin promoter. The cassette encodes a blue fluorescent
protein (BFP) reporter and a 4-OHT-inducible estrogen receptor-type2-conjugated Flp recombinase (Flp-ERT2). Probe positions for Southern
blotting are indicated in both cassette maps; (C) overview of the cloning procedure. Sleeping Beauty mediates stable integration of the
cassettes, followed by porcine SCNT by handmade cloning and transfer of transgenic porcine blastocyst into surrogate landrace sows.
Image of TG pigs at day 357; (D) Southern blot for quantification of cassettes in neonate TG minipig ear fibroblasts probed by either 32P-
dCTP RFP DNA probe or (E) 32P-dCTP Flp DNA probe. Lanes 1–4 depict a 1-kb ladder, WT fibroblast DNA as negative control, and WT
fibroblast DNA spiked by either Flp activator- or oncogene cassette DNA as positive controls. Lanes 5–17 present genomic fibroblast DNA
from 13 TG minipigs. High molecular bands in pigs no. 555 and 563 are likely artifacts. (F) Mapping of the genomic integration site of the
oncogene cassette to a region between the genes NLGN1 and NAALADL2 on chromosome 13 using LDI-PCR in TG minipig no. 556
fibroblasts.
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stomach) and nonintestinal organs (eye, brain, esopha-
gus, heart, kidney, pancreas, bladder, liver, spleen, and
lymph nodes) (Figs 2A,B and S4). We observed tissue
autofluorescence from reflective and bright appearing
organs (including eyes and brain) in both WT and TG
animals that overlapped with the BFP emission spec-
trum, which is a well-known phenomenon (Becker
et al., 2001; Weissleder, 2001). Epifluorescence quan-
tification revealed significantly higher intestinal BFP
expression compared to nonintestinal P = 0.0004, and
background (WT) (P = 0.0002, Wilcoxon signed-rank
test) (Fig. 2B). RFP expression was significantly higher
in all organs of TG pigs compared to background
(WT) (intestinal P = 1.07e-7, nonintestinal P = 8.86e-
5). No difference in RFP expression was observed
between intestinal and nonintestinal TG organs
(P = 0.87). No YFP expression was observed in any
TG organ, indicating that oncogene expression was
efficiently prevented by the polyA stopper without any
leakage (Fig. S4B). The expression pattern of the two
cassettes was confirmed at the mRNA level by RT-
qPCR using organs from TG minipigs (n = 5)
(Fig. 2C). The Flp-ERT2 recombinase mRNA was
only observed in intestinal cells, confirming the intesti-
nal specificity of the used villin promoter, while RFP
expression from the oncogene cassette was observed in
all organs.
3.3. Flp recombinase activates the oncogene
cassette in vitro
Primary TG minipig (n = 3) fibroblasts were isolated
from fetal ear notch biopsies, cultivated, and trans-
fected with a CAG-Flp activator construct to simulate
intestinal Flp activation of the oncogene cassette
(schematized in Fig. 3A). Conventional and droplet
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Fig. 2. Fluorescence reporters and RT-qPCR show intestinal-specific expression of villin-BFP and universal expression of CAG-RFP. (A) IVIS
analysis of isolated organs from TG minipigs (n = 2) and landrace WT pigs (n = 2) depicted are image overlays of bright field and
fluorescence; (B) quantification of the IVIS-collected data on nonintestinal and intestinal organs from two TG pigs and two WT landrace pigs
(for images and raw values, Fig. S4). N.S. = not significant, *P < 0.05. Boxplots indicate the interquartile range and median. Minimum/
maximum values are represented by whiskers and outliers by dots; (C) RT-qPCR-based assessment of RFP and Flp expression in organs
from TG pigs (n = 5). The expression was normalized to the geometric mean of the reference genes RPL4, HPRT, and TBP.
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digital PCR (ddPCR) confirmed Flp recombinase-
mediated excision of the blocking element from the
oncogene cassette (Fig. 3B, C). ddPCR further indi-
cated that the majority of oncogene cassettes (95.2%)
in the sample had been activated (Fig. 3C). This find-
ing was corroborated by flow cytometry, which
showed a complete shift from RFP to YFP and no
nonspecific tissue BFP expression (Fig. 3D). A com-
plete shift from RFP to YFP was also observed by flu-
orescence microscopy (Fig. S5). As expected, no BFP
was observed in the villin-negative fibroblasts. The
activated oncogene unit produced similar levels of
SV40LT, cMYC, and KRAS protein, and showed no
sign of RFP expression (Fig. 3E). DOX treatment of
the Flp recombined TG fibroblasts activated the rtTR-
KRAB and inhibited all expression from the oncogene
unit (Fig. 3E) including removal of YFP emission
(Fig. S5). Transfection with a Dre recombinase, which
can mediate excision of the entire oncogene cassette,
led to reduced oncogene protein levels (Fig. 3E). The
fact that protein remained could indicate that the
oncogene cassette was not excised in all cells.
3.4. 4-OHT treatment of TG intestinal cells
activates the oncogene cassette in vitro and
ex vivo
To assess whether 4-OHT treatment activates the
oncogene cassette, organoid cultures were established
from intestinal biopsies from TG minipigs (n = 5) and
treated with 1 lM 4-OHT upon crypt formation. Flp
recombination of the oncogene cassette was confirmed
in all 4-OHT-treated cultures (Fig. 4A–D). Using
ddPCR, it was estimated that ~ 1.38% (1/27) of onco-
gene cassettes were recombined. Nonetheless, the
induced SV40LT mRNA expression could easily be
detected, indicating that the CAG promoter ensures
high transcriptional activity (Fig. 4D). The RFP level
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Fig. 3. In vitro activation of the oncogene cassette through CAG-Flp transfection. (A) Schematics of Flp-mediated activation of oncogene
cassette. Arrows indicate primers for the transition PCR assay (1–2) and for the three ddPCR assays; pig genome (3–4), oncogene cassette
(5–6), and recombination (7–8); (B) validation of recombination in Flp-transfected TG fibroblasts using the transition PCR assay. The expected
transition band of 972 bp is seen in Flp-transfected TG fibroblasts, but not in untransfected, or WT fibroblasts; (C) ddPCR quantification of
pig genomes, oncogene cassettes, and recombination events in WT, TG- and TG CAG-Flp-transfected fibroblasts. Plotted are mean  SE,
normalized to pig genome equivalents for three biological replicates; (D) flow cytometric assessment of BFP, RFP, and YFP fluorescence
from WT, TG- and TG CAG-Flp-transfected pig fibroblasts (n > 10 000 cells in each analysis). All fibroblasts are BFP negative as expected.
There is a complete shift from RFP to YFP in TG fibroblasts upon Flp transfection. Shown is a representative example of three independent
experiments; (E) western blotting of untreated TG fibroblast, CAG-Flp-transfected TG fibroblasts with either DOX treatment or subsequent
CAG-Dre recombinase transfection. Anti-2A linker peptide antibody was used to visualize multiple protein expression with b-actin as loading
control. The anti-2A linker peptide antibody also recognizes various porcine teschovirus proteins, which results in a few unspecific bands in
the immunoblot.
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was largely unchanged, as expected with only 1 of 27
oncogene cassettes recombined. Activation of the
oncogene cassette was also tested ex vivo. Fresh colo-
nic and rectal biopsies from TG minipigs (n = 6) were
treated with 1 lM 4-OHT. Recombination was seen in
all treated biopsies at rates ranging from 0.04 to
0.74% (Fig. 4B,C). This confirmed that the oncogene
cassette could be activated in both colonic epithelium
and rectal epithelium.
3.5. Metastatic cancer in vivo
Encouraged by our ability to activate the oncogene cas-
sette in intestinal biopsies ex vivo, systemic tamoxifen
treatment was initiated. Tamoxifen was administered
perorally to TG minipigs (n = 3) (400 mg per day) for
2 9 5 days with a 7-day break in between. Two pigs
were sacrificed 72 days after treatment initiation; a duo-
denal tumor with metastatic spread to a local lymph
node was detected in one of the pigs (Fig. 5A). The
other pig showed no signs of tumor growth or activation
of the oncogene cassette, neither did the third pig that
was sacrificed 218 days after treatment initiation (data
not shown). ddPCR analysis of the duodenal tumor and
lymph node metastasis showed that 30–50% of the
oncogene cassettes were activated (Fig. 5B). Given that
all TG cells have one oncogene cassette, this indicates
that 50–70% of the cells in the tumor lesions are of
nonepithelial origin or normal unactivated epithelial
cells. Consistent with activation, and excision of the
blocker element (including the RFP reporter) in cancer
cells, the RFP transcript level in biopsies from tumor
and metastasis was reduced 0.38-fold (95% CI: 0.36–
0.40) compared to adjacent normal tissue (Fig. 5C). By
contrast, the transcript levels of the oncogene KRAS
was increased 4.36-fold (95% CI: 4.20–4.53), and
de novo SV40LT transcription was detected. Exogenous
SV40LT protein was consistently found in tumor cells
(100%), but not in adjacent normal epithelia and con-
nective tissue (Fig. 5D). The cancer cells in the duodenal
tumor and lymph node both expressed the epithelial
marker CDX2, as well as the neuroendocrine markers
CD56, and synaptophysin (Fig. 5E), indicating that the
metastasis originated from the duodenal tumor. The
neuroendocrine markers were highly expressed in the
membrane and cytoplasm in the majority of the primary
tumor (85–90%), while the epithelial marker CDX2 was
focally positive in 60% of the primary tumor. The same
staining patterns were seen in the lymph node metastasis
(Fig. 5E). Histopathology was assessed blinded by an
experienced pathologist and showed invasion into mus-
cularis propria, indicating a pT2, pN1 large cell neu-
roendocrine tumor (NET). The proliferation marker
KI67 was positive in roughly 90% of the carcinoma and
metastasis (Fig. 5E). There were no signs of tumor for-
mation in the remaining treated pigs (n = 2), in WT pigs
treated with the same tamoxifen dose (n = 9), or in
untreated TG pigs (n = 2).
4. Discussion
In this study, we have successfully generated an induci-
ble oncopig model. The study was a small (n = 3)
proof-of-principle study with the primary goal of
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inducing intestinal cancer. Upon systemic treatment
with tamoxifen, we observed a carcinoma with lymph
node metastasis already 2 months post-treatment in
one of three pigs. Animal models are important tools
for cancer research. Pigs resemble humans in regard
to, for example, size, physiology, and lifespan.
Although pigs are more costly and require more space
than rodent models, results from studies of pigs might
be easily translated directly to the clinic. Unlike pig
models for spontaneous cancer that require long time
for cancer development (Duran-Struuck et al., 2010),
the model presented here developed metastatic disease
only two months after activation. The large size of
pigs and their overall similarity to humans open up for
novel in vivo experiments of intestinal cancer, enabling
treatment response studies, with longitudinal sample
collection from the primary tumor. The present model
is inducible and, compared to spontaneous models,
highly controllable. In principle, it should be possible
to target the intestinal epithelium directly by delivery
of 4-OHT through endoscopy, potentially opening up
for parallel initiation of multiple tumors allowing for
synchronous replicates in different areas of the intes-
tine in the same pig.
Fig. 5. In vivo carcinogenesis after systemic tamoxifen treatment. (A) A duodenal tumor and an enlarged local lymph node were found in
the resected specimen; (B) quantification of the number of oncogene cassettes and recombination events by ddPCR in adjacent normal
duodenal epithelium and biopsies of the tumor (T1 and T2) and lymph node; (C) RFP, KRAS, and SV40LT transcription levels in adjacent
normal tissue, carcinoma, and lymph node, quantified by RT-PCR; (D) immunohistochemistry reveals the carcinoma cells to be SV40LT
positive; (E) H&E and IHC for the duodenal tumor and lymph node metastasis with the neuroendocrine differentiation markers
synaptophysin and CD56, as well as the intestinal epithelial marker CDX-2 and the proliferation marker Ki-67.
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As an initial in vivo test of the model, we used sys-
temic tamoxifen treatment. While one might have
expected that this would cause tumors throughout the
intestine, we observed a single tumor only, located in
the small intestine of one of the pigs. We speculate that
this may be due to either a low activation rate, for
example, due to a low 4-OHT concentration in the
mucosal layer, or that activation of the oncogene cas-
sette does not induce sufficient stem cell properties,
meaning that activated differentiated cells continue to
migrate up the crypt–villus axis for eventually to be
exfoliated. This would mean that only if the activated
cell is a stem cell, it is likely that a tumor will be
formed. The low frequency of recombination observed
in the organoids and treated biopsies indicates that
only few cells are activated either due to low 4-OHT
accessibility, due to low efficiency of the 4-OHT-
activated Flp-ERT2 recombinase, or due to a high
fraction of the cells in the biopsies being nonintestinal
cells (which do not express Flp-ERT2) incapable of
activation. Another explanation could be that onco-
gene cassette activation in intestinal cells leads to apop-
tosis. It has been reported that high expression of
KRAS and cMYC, as well as inhibition of p53/pRb,
can induce apoptosis (Podsypanina et al., 2008). We
did not observe any activation in the adjacent normal
mucosa, supporting the view that either activation
levels are low or activated cells have died or been exfo-
liated during the two-month period from 4-OHT treat-
ment until the pigs were sacrificed. One or more of
these mechanisms potentially also explain why only
one of three 4-OHT-treated TG minipigs developed
cancer. We further speculate that the localization of the
tumor in the small intestine is a consequence of the
systemic treatment, where a higher concentration of
4-OHT is to be expected, due to tamoxifen being
metabolized in the liver and partly secreted as the
active metabolite 4-OHT through the bile (Fromson
et al., 1973). Characterization of the duodenal tumor
showed that it was of epithelial origin and followed the
neuroendocrine differentiation lineage. Unlike human
duodenal NETs, this tumor was highly malignant and
produced lymph node metastasis within 2 months. Per-
haps this was expected as the oncogenesis in this model
is driven by overexpression of cMYC, KRAS-G12D,
and SV40LT, of which the latter inhibits the tumor
suppressors p53 and pRB. This combination is rarely
observed in human duodenal NETs, but in contrast is
frequently observed in the more aggressive NETs and
other carcinomas of the colon (Kleist et al., 2014), rais-
ing the concern that the presented model might not
fully reflect the etiology of human intestinal cancers.
However, our rationale for deregulating four of the
most potent cancer pathways (cMYC, KRAS, p53, and
pRB) was primarily to increase the likelihood of fast
development of full-blown tumors. Additional studies
using more oncopigs are needed to characterize the
prevalence and biology of the tumors produced, and
their relation to human cancer.
Until now, no pig model has been reported to pro-
duce intestinal carcinomas. A recent study reported an
APC-mutated pig (Flisikowska et al., 2012), which
yielded multiple adenomas in the colon; however, none
developed into carcinomas. Introducing a latent onco-
genic mutated p53 into transformed porcine mesenchy-
mal cells leads to in vivo lymphoma, renal, and
osteogenic tumors (Leuchs et al., 2012; Sieren et al.,
2014). Likewise, a porcine Cre-inducible model with
p53 and KRAS mutations (Schook et al., 2015)
described that tumors of mesenchymal origin developed
at AdCre injection sites. The advantage of our model is
the direct targeting of intestinal epithelia through the
villin-controlled Flp-ERT2 expression. This is clinically
more relevant than a model where any cell type has the
potential of transforming into cancer upon injection of
the activating agent. Note, however, that the AdCre
model by Schook et al., as well as our pig model in
principle, can be activated tissue specifically if the deliv-
ered recombinase (Flp or Cre) is controlled by a tissue-
specific promoter. Using such an approach, the onco-
gene cassette could potentially be activated in any
organ, including pancreas and lung where KRAS and
p53 often are deregulated in tumors.
We foresee great potential for the presented model,
particularly if an approach for targeted initiation of car-
cinogenesis is established, for example, by injections of
4-OHT directly into the intestinal wall. It will be critical
to ensure sufficiently high concentrations of 4-OHT and
long enough retention time of the drug for the activa-
tion of sufficient numbers of intestinal stem cells at the
injection site. ERT2-inducible murine models are com-
monly activated by intraperitoneal injection of 4-OHT
oil solutions. However, in minipigs, such approach
would require large quantities of 4-OHT and the risk of
hazardous oil-induced inflammation (Marques da Silva
et al., 2008; Ziv et al., 2015). Alternative delivery sys-
tems could involve electroporation, osmotic pumps,
and/or 4-OHT-loaded nanoparticles (Devulapally et al.,
2015). Tumor initiation in the distal colon would allow
easy access to collect biopsies through endoscopies
enabling longitudinal studies. Such studies would allow
cancer progression and clonal evolution to be studied
over time both in the absence and in the presence of
therapy-induced selection. Such longitudinal studies are
not possible in humans, where it is unethical not to
remove the primary tumor.
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In summary, we have generated the first inducible
oncopig model of intestinal cancer. As discussed
above, the current interpretation of the study is limited
by several factors, most notably (a) a low number of
animals used; (b) a single event of successful carcino-
genesis; (c) the unknown relation between the observed
NET tumor and the biology of human intestinal can-
cers; (d) the lack of control of 4-OHT delivery when
given systemically. However, the model also provides a
range of novel and unique possibilities to explore
intestinal carcinogenesis from initiation and all the
way to metastasis.
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